ArticleDisease models & mechanisms2025
Murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer.
Article in Disease models & mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Preclinical modeling of epithelial ovarian cancer in immune-competent mice progressing to orthotopic, spontaneous tumors is challenging, requiring multiple genetic modifications in the host. Transplantable models using cell lines are easier to implement than spontaneous animal models, given that they reproduce the key disease characteristics. To create new in vivo ovarian tumor models, we generated 28 murine ovarian cancer cell lines with distinct genetic traits, such as deletion of Trp53, activation of KrasG12D, or deletion of Pten or KrasG12D/Pten-/- combination. Two distinct Trp53 null cell lines recapitulate high-grade serous histology when orthotopically injected into immune-competent, syngeneic hosts. Cells with Pten deletion trigger high-grade endometrioid tumors, and cells with dual KrasG12D activation and Pten deletion model carcinosarcoma. The cells express different tumor antigens, secrete varying levels of cytokines and chemokines, and trigger tumors with diverse inflammation profiles and various intratumoral T- and B-lymphocyte infiltration patterns. RNA-sequencing data from 16 cell lines reveal the gene expression profile across distinct models with different histotypes. This versatile collection of murine cell lines supports translationally relevant studies in ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.